Round Up

Five things for pharma marketers to know: Friday, August 11, 2017

Five things for pharma marketers to know: Friday, August 11, 2017

By

Egalet slashes workforce in favor of opioid education; Novo's experimental obesity drug reports positive results; Trump declares opioid crisis a national emergency

Five things for pharma marketers to know: Thursday, August 3, 2017

Five things for pharma marketers to know: Thursday, August 3, 2017

By

FDA committee votes against J&J arthritis drug; scientists successfully edit genes; Shire mulls ADHD spin off

Five things for pharma marketers to know: Friday, July 14, 2017

Five things for pharma marketers to know: Friday, July 14, 2017

By

The FDA approves J&J psoriasis drug; PARP inhibitors are not cost-effective, ICER says; Verily releases mosquitoes to combat Zika

Five things for pharma marketers to know: Wednesday, July 5, 2017

Five things for pharma marketers to know: Wednesday, July 5, 2017

By

Amgen and Teva raise prices of leukemia drugs twice this year; Roche acquires diabetes app; docs use Snapchat to share patient scans

Five things for pharma marketers to know: Friday, June 30, 2017

Five things for pharma marketers to know: Friday, June 30, 2017

By

The FDA plans to review orphan drug backlog; drugmaker supported charity helped patients pay for donor's drugs; low dose Xarelto gets Priority Review

Five things for pharma marketers to know: Wednesday, June 28, 2017

Five things for pharma marketers to know: Wednesday, June 28, 2017

By

Lawmakers delay healthcare bill vote; Merck affected by cyberattack; more young people are having strokes

Five things for pharma marketers to know: Monday, June 26, 2017

Five things for pharma marketers to know: Monday, June 26, 2017

By

The performance of generic drugs is not always guaranteed; the FDA approves a new blood thinner; Gottlieb wants rejection letters public

Five things for pharma marketers to know: Friday, June 23, 2017

Five things for pharma marketers to know: Friday, June 23, 2017

By

Novartis drug prevents heart attacks and strokes, per trial; Senate lawmakers unveil healthcare bill; Pfizer receives CRL for Epogen biosimilar

Five things for pharma marketers to know: Tuesday, June 20, 2017

Five things for pharma marketers to know: Tuesday, June 20, 2017

By

Novartis reports positive Phase-III results for Eylea competitor; AZ faces "critical transition point" in MYSTIC trial; physician shortage expected to rise

Five things for pharma marketers to know: Tuesday, June 13, 2017

Five things for pharma marketers to know: Tuesday, June 13, 2017

By

Alkermes lobbies lawmakers on its opioid addiction drug; rep salaries rise; SCOTUS rules in favor of Sandoz in biosimilar suit

Five things for pharma marketers to know: Thursday, June 8, 2017

Five things for pharma marketers to know: Thursday, June 8, 2017

By

Novartis CAR-T drug boasts competitive response rates; WPP reports slowing sales for healthcare business; AZ sells migraine drug

Five things for pharma marketers to know: Wednesday, May 31, 2017

Five things for pharma marketers to know: Wednesday, May 31, 2017

By

BMS partners on Opdivo combo; one-quarter of insurers have signed an outcomes-based contract with a drugmaker; rebates do not lead to savings for Medicare beneficiaries

Five things for pharma marketers to know: Wednesday, May 24, 2017

Five things for pharma marketers to know: Wednesday, May 24, 2017

By

Keytruda receives first approval based on a genetic feature and not tumor's location; Alexion reps reportedly crossed ethical lines; profits up at insurers

Five things for pharma marketers to know: Monday, May 22, 2017

Five things for pharma marketers to know: Monday, May 22, 2017

By

Amgen's osteoporosis drug set back by safety issue; new FDA digital biz to hire 13 engineers; Celgene's MS drug bests Avonex in trial

Five things for pharma marketers to know: Friday, May 19, 2017

Five things for pharma marketers to know: Friday, May 19, 2017

By

Keytruda gets two new FDA approvals; lawmakers aim to speed up approval of generics; Incyte uses soap opera to spread rare-disease awareness

Five things for pharma marketers to know: Friday, May 12, 2017

Five things for pharma marketers to know: Friday, May 12, 2017

By

AstraZeneca's Imfinzi improves survival in lung cancer in trial; Blue Cross Blue Shield partners with Lyft; Lilly to submit migraine drug to FDA

Five things for pharma marketers to know: Friday, May 5, 2017

Five things for pharma marketers to know: Friday, May 5, 2017

By

CVS formulary changes lifted Tresiba sales; Novartis licenses NASH drug; FDA is building digital health unit

Five things for pharma marketers to know: Tuesday, April 25, 2017

Five things for pharma marketers to know: Tuesday, April 25, 2017

By

Sanofi sues Mylan over anticompetitive practices; Anthem to drop Express Scripts; GSK chief digital officer says advertisers should focus on fewer publishers

Five things for pharma marketers to know: Thursday, April 20, 2017

Five things for pharma marketers to know: Thursday, April 20, 2017

By

Tesaro discloses price for new drug that differs from FDA-approved dosage; uniQure discontinues Glybera; O'Reilly leaves Fox

Five things for pharma marketers to know: Wednesday, April 19, 2017

Five things for pharma marketers to know: Wednesday, April 19, 2017

By

Valeant gave $100,000 to patient group to address affordability of its drug; Omnicom reports 3% increase in specialty group revenue; Verily to study biometric data

Five things for pharma marketers to know: Thursday, April 13, 2017

Five things for pharma marketers to know: Thursday, April 13, 2017

By

Biogen licenses experimental Alzheimer's drug; Apple reportedly working on diabetes sensors; doc warns against industry payments

Five things for pharma marketers to know: Wednesday, April 12, 2017

Five things for pharma marketers to know: Wednesday, April 12, 2017

By

The FDA approves first drug to treat tardive dyskinesia; Americans use crowdfund sites to pay for prescriptions; stroke sufferers struggle with adherence

Five things for pharma marketers to know: Friday, April 7, 2017

Five things for pharma marketers to know: Friday, April 7, 2017

By

The FDA rejected an outcomes update to the Januvia label; digital-health funding dropped in Q1 of 2017; the FDA approves 23andMe's genetic test

Five things for pharma marketers to know: Tuesday, April 4, 2017

Five things for pharma marketers to know: Tuesday, April 4, 2017

By

Mylan allegedly increased EpiPen list price to appease PBMs; 20% of patients misdiagnosed by primary-care doctor: study; Mallinckrodt settles DEA probe

Five things for pharma marketers to know: Thursday, March 30, 2016

Five things for pharma marketers to know: Thursday, March 30, 2016

By

Novartis CAR-T drug receives priority review; addiction center's ad compares addiction to cancer; Arizona passes off-label law

Five things for pharma marketers to know: Tuesday, March 28, 2017

Five things for pharma marketers to know: Tuesday, March 28, 2017

By

Ovarian cancer drug nabs FDA approval; Senate committee to investigate opioid manufacturers; Allergan's acne drug reports positive Phase-III results

Five things for pharma marketers to know: Thursday, March 23, 2017

Five things for pharma marketers to know: Thursday, March 23, 2017

By

AHCA set for vote; J&J halts YouTube ads; approval decisions loom for Sanofi, Roche

Five things for pharma marketers to know: Tuesday, March 21, 2017

Five things for pharma marketers to know: Tuesday, March 21, 2017

By

Eli Lilly claims it only realizes small percentage of list price increases; PBMs become latest target in pricing backlash; AHCA revised

Five things for pharma marketers to know: Thursday, March 9, 2017

Five things for pharma marketers to know: Thursday, March 9, 2017

Companies form alliance to lower healthcare costs; the EMA cautions doctors on switching patients to biosimilars; analyst says Remicade suit may be settled

Five things for pharma marketers to know: Tuesday, March 7, 2017

Five things for pharma marketers to know: Tuesday, March 7, 2017

By

GOP unveils ACA replacement; Trump is working on new drug-pricing system; researchers to study thousands of immunotherapies